One of the many concerns about President Obama’s health care legislation is that it will encourage—if not eventually require—the government to approve the cheapest rather than the best ...

But one holds a clear price advantage. Avastin costs about $50 per injection. Lucentis costs about $2,000 per injection. Doctors choose the more expensive drug more than half a million times every ...

While Avastin is designed to treat cancer, not blindness, many doctors say it works just as well as Lucentis — with significant potential cost savings to patients, insurers, and the government.

Full publication of results from the head-to-head study of Avastin (bevacizumab) and Lucentis (ranibizumab) in "wet" age-related macular degeneration (AMD) confirmed information previously leaked ...

The valuation of Genentech shares is "less attractive," said SG Cowen, as blockbuster cancer drug Avastin could limit the potential of the biotech firm's promising blindness treatment, Lucentis.

But one holds a clear price advantage. Avastin costs about $50 per injection. Lucentis costs about $2,000 per injection. Doctors choose the more expensive drug more than half a million times every ...

Inhibitors of vascular endothelial growth factor — bevacizumab (Avastin) and ranibizumab (Lucentis) — are used to treat patients with neovascular age-related macular degeneration. Bevacizumab ...

“So what were the treatment options available? At that point, we had only three drugs available, Avastin, Lucentis, and Eylea. However, you can see the bottom part where we have a long list of ...

Avastin and Lucentis: two drugs with roughly the same molecular structure, both manufactured by the same drugmaker. One is approved to treat cancer, the other wet age-related macular degeneration.

More fuel for the Avastin-vs-Lucentis debate: A big U.S. government study of the two drugs deemed them more or less equivalent for treating age-related macular degeneration. It's a finding that ...

A new study, led by Dr. Daniel Martin, an ophthalmologist at the Cleveland Clinic’s Cole Eye Institute, has found that the cancer drug Avastin delivers the same benefits of the drug Lucentis ...

It concludes that the company's two drugs, Avastin and Lucentis, are equally effective at treating the leading cause of blindness in people over age 65, but that Roche has manipulated their supply ...